The Xmas present for women's health: A strike to osteoporosis prevention

Maturitas

Volumn 48, Issue 1, 2004, Pages 9-11

  Gambacciani, Marco ^a   Genazzani, Andrea R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; HORMONE; PARATHYROID HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; CALCIUM INTAKE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FEMALE; FRAGILITY FRACTURE; HEALTH; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRESCRIPTION; PROPHYLAXIS; RELIABILITY; RISK BENEFIT ANALYSIS; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WELLBEING;

ESTROGEN REPLACEMENT THERAPY; EUROPE; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES; WOMEN'S HEALTH;

EID: 1942521404     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.01.007     Document Type: Editorial

References (15)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
2. Cauley J.A., Robbins J., Chen Z., Cummings S.R., Jackson R.D., LaCroix A.Z., et al. Women's health initiative investigators: effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. J. Am. Med. Assoc. 290:2003;1729-1738
3. Ott S.M. Bisphosphonates should not be recommended for women aged 50. Br. Med. J. 326:2003;1398
4. Rymer J., Wilson R., Ballard K. Making decisions about hormone replacement therapy. Br. Med. J. 326:2003;322-326
5. Marcus R., Wong M., Heath H. III, Stock J.L. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrinol. Rev. 23:2002;16-37
6. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100:1997;1475-1480
7. Clemett D., Spencer C.M. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs. 60:2000;379-411
8. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J. Am. Med. Assoc. 282:1999;637-645
9. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J. Am. Med. Assoc. 281:1999;2189-2197
10. Chlebowski R.T., Hendrixm S.L., Langer R.D., Stefanick M.L., Gass M., La Rodabough R.J., et al. Women's Health Initiative Investigators Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women' Health Initiative randomized trial. J. Am. Med. Assoc. 289(24):2003;3243-3253
11. Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II; hormone replacement therapy and cancer. In: Proceedings of the International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. Climacteric 2001;4(3):181-93.
12. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet 2003;362:419-27.
13. Gambacciani M., Genazzani A.R. The study with a million women (and hopefully fewer mistakes). Gynecol. Endocrinol. 17:2003;1-4
14. Lindsay R., Gallagher J.C., Kleerekoper M., Pickar J.H. Effects of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J. Am. Med. Assoc. 287:2002;2668-2676
15. Gambacciani M., Genazzani A.R. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas. 40(3):2001;195-201